Flufenamic acid

Flufenamic acid, flufenamic acid, 530-78-9, Arlef, Fluphenamic acid, Achless, 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid, N-(3-Trifluoromethylphenyl)anthranilic acid, Acido flufenamico, Flufenaminsaeure, Meralen, 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid, Acide flufenamique, CI 440, NSC-82699, 2-[3-(Trifluoromethyl)anilino]benzoic acid, Acidum flufenamicum, 2-[[3-(Trifluoromethyl)phenyl]amino]benzoic acid, CN-27,554, 3'-Trifluoromethyldiphenylamine-2-carboxylic acid, INF-1837, Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, DTXSID7023063, Benzoic acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 60GCX7Y6BH, N-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid, NSC-219007, CHEBI:42638, CI-440, CN-27554, DTXCID303063, Acid, Flufenamic, 2-(3-(trifluoromethyl)anilino)benzoic acid, flufenamic acid aluminium, RefChem:388982, M01AG03, 208-494-1, Fullsafe, Nichisedan, Tecramine, Paraflu, Parlef, Flufacid, Lanceat, Plostene, Parlif, Surika, Reumajust A, Ristogen, Sastridex, Ansatin, Fluore-200, ANT-1, TVX 916, INF 1837, MFCD00002422, C.I. 440, NSC 219007, 2-(3-Trifluoromethylanilino)benzoic Acid, N-[3-(Trifluoromethyl)phenyl]anthranilic acid, 2-((3-Trifluromethyl)phenyl)aminobenzoic acid, 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID, N-(m-Trifluoromethylphenyl)-2-aminobenzoic acid, CHEMBL23588, MLS000028563, Saal-F, NCGC00016490-06, CAS-530-78-9, SMR000059027, N-(3-Trifluoromethylphenyl)-anthranilic acid, WLN: QVR BMR CXFFF, FFA, F0909-0007, Flufenamicacid, N-(.alpha.,.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid, Flufenaminsaeure [German], Acido flufenamico [Italian], FLF, CCRIS 5266, 2-[(3-Trifluromethyl)phenyl]aminobenzoic acid, N-[(3-Trifluoromethyl)phenyl]anthranilic acid, Acide flufenamique [INN-French], Acido flufenamico [INN-Spanish], Acidum flufenamicum [INN-Latin], N-((m-Trifluoromethyl)phenyl)-2-aminobenzoic acid, N-[(m-Trifluoromethyl)phenyl]-2-aminobenzoic acid, N-[m-(Trifluoromethyl)phenyl]-2-aminobenzoic acid, SR-01000000241, EINECS 208-494-1, Anthranilic acid,.alpha.,.alpha.-trifluoro-m-tolyl)-, N-(.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid, UNII-60GCX7Y6BH, Flufenamic acid [USAN:INN:BAN:JAN], BRN 1996069, flufenamic-acid, Prestwick_220, Arlef (TN), Spectrum_001257, 1bm7, Opera_ID_578, Prestwick0_000203, Prestwick1_000203, Prestwick2_000203, Prestwick3_000203, Spectrum2_000789, Spectrum3_001273, Spectrum4_000102, Spectrum5_000686, Etofenamate EP Impurity A, Epitope ID:613429, EC 208-494-1, Flufenamic acid (Standard), CBiol_001756, SCHEMBL17497, BSPBio_000185, BSPBio_001319, BSPBio_002866, CBDivE_012649, FLUFENAMIC ACID [MI], KBioGR_000039, KBioGR_000424, KBioGR_002267, KBioSS_000039, KBioSS_001737, KBioSS_002268, 3-14-00-00905 (Beilstein Handbook Reference), MLS001148610, DivK1c_000581, FLUFENAMIC ACID [INN], FLUFENAMIC ACID [JAN], SPECTRUM1501015, SPBio_000898, SPBio_002106, FLUFENAMIC ACID [USAN], BPBio1_000205, GTPL2447, orb1310228, FLUFENAMIC ACID [MART.], SCHEMBL29356958, BCBcMAP01_000039, BDBM17636, HMS501N03, HY-B1221R, KBio1_000581, KBio2_000039, KBio2_001737, KBio2_002267, KBio2_002607, KBio2_004305, KBio2_004835, KBio2_005175, KBio2_006873, KBio2_007403, KBio3_000077, KBio3_000078, KBio3_002366, KBio3_002747, Anthranilic acid, N-(alpha,alpha,alpha-trifluoro-m-tolyl)-, FLUFENAMIC ACID [WHO-DD], MSK8002, cMAP_000004, NINDS_000581, Bio1_000042, Bio1_000531, Bio1_001020, Bio2_000039, Bio2_000519, Flufenamic acid (JAN/USAN/INN), GLXC-27023, HMS1361B21, HMS1568J07, HMS1791B21, HMS1921B21, HMS1989B21, HMS2089E07, HMS2092B09, HMS2095J07, HMS2232G24, HMS3371F01, HMS3402B21, HMS3652F06, HMS3712J07, HMS3885P15, HMS5082J22, Pharmakon1600-01501015, SMSSF-0062312, HY-B1221, NSC82699, Tox21_110452, Tox21_302111, CCG-40167, EBC-04210, MSK8002-100A, NSC219007, NSC757823, s4268, SBB001140, STK985630, AKOS000265536, MSK8002-1000A, Tox21_110452_1, CS-4811, DB02266, FF23323, KS-1143, NSC-757823, Etofenamate EP Impurity A (Free Base), IDI1_000581, IDI1_033789, NCGC00016490-01, NCGC00016490-02, NCGC00016490-03, NCGC00016490-04, NCGC00016490-05, NCGC00016490-07, NCGC00016490-08, NCGC00016490-09, NCGC00016490-10, NCGC00016490-12, NCGC00023200-03, NCGC00023200-04, NCGC00023200-05, NCGC00023200-06, NCGC00023200-07, NCGC00255175-01, CN-27544, ST026563, SY014664, SBI-0051633.P002, DB-052254, 2-[3-(trifluoromethyl)anilino]-benzoic acid, AB00052198, ETOFENAMATE IMPURITY A [EP IMPURITY], n-(a,a,a-trifluoro-m-tolyl)anthranilic acid, NS00000475, SW196528-3, UNM000001246003, 2-[3-(Trifluoromethyl)anilino]benzoic acid #, EN300-16858, o-[m-(trifluoromethyl)phenylamino]benzoic acid, 2-[(3-Trifluoromethylphenyl)amino]benzoic Acid, D01581, D97458, AB00052198-14, AB00052198_15, F358173, Q416341, 3'-Trifluoromethyldiphenylamine-2-carbox ylic acid, Flufenamic acid Solution in Acetonitrile, 100ug/mL, SR-01000000241-2, SR-01000000241-3, BRD-K44067360-001-06-3, BRD-K44067360-001-16-2, BRD-K44067360-001-29-5, BRD-K44067360-001-30-3, Flufenamic acid Solution in Acetonitrile, 1000ug/mL, Z56797275, Flufenamic acid, analytical standard, for drug analysis, Anthranilic acid, N-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-, FFA, Flufenamic acid, 3-[(2-Carboxyphenyl)amino]benzotrifluoride, 2-Carboxy-3'-(trifluoromethyl)diphenylamine